<img src="https://ml.globenewswire.com/Resource/Download/a8137a61-b858-48da-9e47-1f1bf8f6ddba?size=2" nborder="0" align="left" hspace="5" vspace="5" title="profusa_logo.jpg" alt="Profusa, Inc."/>BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to questions received from its European Notified Body, GMED, following the successful completion of the Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED as part of the MDR conformity assessment process for the Lumee® Oxygen Platform. The response package included updates across multiple aspects of the MDR submission, including technical documentation, quality system evidence, clinical evaluation activities, and supporting validation information. The submission represents an important step in the Company's ongoing efforts to obtain CE Mark certification for the Lumee Oxygen Platform and supports Profusa's broader strategy to commercialize the technology in Europe. "Submitting our responses to GMED marks another meaningful milestone in the CE Mark review process," said Ben Hwang, Ph.D., Profusa’s Chairman and Chief Executive Officer. "We appreciate GMED's continued engagement throughout the assessment and remain committed to working collaboratively with the agency as it completes its review. We believe the Lumee Oxygen Platform has the potential to address a significant unmet need by providing clinicians with continuous, real-time tissue oxygen monitoring, and we look forward to advancing toward European commercialization." The CE Mark review process remains ongoing, and there can be no assurance regarding the timing or outcome of GMED's assessment. Profusa will continue to support the review process and provide updates on material regulatory milestones as appropriate. About the Lumee® Oxygen Platform The Lumee Oxygen Platform is designed to provide continuous, real-time monitoring of tissue oxygen levels through Profusa's proprietary tissue-integrated biosensor technology. The platform is intended to provide clinicians with objective tissue perfusion data that may support treatment decision-making and patient monitoring. About Profusa Based in Berkeley, CA, Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on. “LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=tfWFGshBfBTwGjsiicC3lN2hhDy2eNPyBIvGDPlsHeeqb_NMiLGgYRNaqsIu-zaIPTpUd5Kf0oUqTvP33_J5n0FXeiUT80fhMBDbfJwfoIU=" rel="nofollow" target="_blank" title="">https://profusa.com.</a> Special Note Regarding Forward-Looking Statements Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa, including statements regarding the proposed acquisition, the anticipated launch of PanOmics DX™, and Profusa’s strategic plans. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements including, without limitation, risks related to the Company's planned European and U.S. product launches, the risk that such product launches may not result in revenue at the levels anticipated, the risk that customer demand may be less than expected, and risks relating to the Company’s withdrawal of the Registration Statement and conducting a smaller offering of its securities. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described more fully in the Company's public filings made by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate. No Offer or Solicitation This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”), or in a transaction exempt from the registration requirements of the Securities Act. Contacts Investor and Media Contacts email:  <a href="https://www.globenewswire.com/Tracker?data=3iXmwwYv3C5CwTrdgVf23NwJ_C_lfXSJ2ztxQqCJ2-fEsOKvjsrMlfVyq-V6WViwUZfNCBVKH-nF2w-M5KbGdJyuk67frx9X02Tn_-VmO9k=" rel="nofollow" target="_blank" title="info@coreir.com">info@coreir.com</a> phone:  1 (212) 655-0924 <img alt="" src='https://ml.globenewswire.com/media/MGZjMzYyYzYtN2Y2ZS00MTMzLTgwNjItYzY0ZDk1Mjc1MTNkLTUwMDA5ODI1NC0yMDI2LTA2LTEyLWVu/tiny/Profusa-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn